Anbio Biotechnology is a Germany-based medical device company. The Company is engaged in the development of medical technology and the provision of in vitro diagnostics (IVD) products. Its products offer solutions for over the counter (OTC) use, point-of-care (POCT) settings, and laboratory applications, ensuring that both healthcare providers and patients have access to reliable and efficient diagnostic tools in any setting. Its IVD products detect a wide range of biomarkers across critical medical fields, including infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Some of its IVD platforms: Chemiluminescence Immunoassay (ChLIA), Lateral Flow Immunoassay (LFIA), Fluorescent Immunoassay (FIA), Polymerase Chain Reaction (PCR) and Loop-mediated Isothermal Amplification (LAMP).
公司代碼NNNN
公司名稱Anbio Biotechnology
上市日期Feb 19, 2025
CEOLau (Michael)
員工數量27
證券類型Ordinary Share
年結日Feb 19
公司地址Friedrich-Ebert-Anlage 49
城市FRANKFURT AM MAIN
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Germany
郵編60308
電話4916096247281
網址https://anbiobiotechnology.com/
公司代碼NNNN
上市日期Feb 19, 2025
CEOLau (Michael)